Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Imfinzi (durvalumab)
Pharma
AstraZeneca’s Imfinzi tackles another type of lung cancer
The result builds on the immunotherapy’s existing FDA clearance in stage 3 non-small cell lung cancer and extensive-stage small cell lung cancer.
Angus Liu
Apr 5, 2024 10:22am
AZ, GSK make case for broad I-O uses in endometrial cancer
Mar 18, 2024 11:05am
Merck claims digital crown, holding off challenge from AZ, BMS
Mar 15, 2024 10:30am
AZ charts new but uncertain path for Imfinzi in liver cancer
Jan 19, 2024 10:00am
GSK tees up AstraZeneca rivalry with Jemperli-Zejula combo data
Dec 18, 2023 11:13am
AstraZeneca suffers setback in ambitious 2030 lung cancer goal
Nov 14, 2023 11:05am